Pinteon Therapeutics is a US biotechnology company developing therapeutics targeting tau protein pathology in Alzheimer's disease and other neurodegenerative disorders. Founded in 2016 and headquartered in San Francisco, California, Pinteon takes a unique approach by targeting specific conformational epitopes of tau that are exposed only in pathological forms of the protein["@pinteon"].
...
Pinteon Therapeutics
Overview
Mermaid diagram (expand to render)
Pinteon Therapeutics is a US biotechnology company developing therapeutics targeting tau protein pathology in Alzheimer's disease and other neurodegenerative disorders. Founded in 2016 and headquartered in San Francisco, California, Pinteon takes a unique approach by targeting specific conformational epitopes of tau that are exposed only in pathological forms of the protein["@pinteon"].
The company's pioneering conformant antibody technology allows selective targeting of disease-causing tau species while sparing normal tau function, potentially providing therapeutic benefit with improved safety compared to non-selective approaches["@conformant2020"].
Company Overview
| Attribute | Value | |-----------|-------| | Ticker | NASDAQ: PNTB (formerly) | | Founded | 2016 | | Headquarters | San Francisco, CA | | CEO | Martin R. Jeffries | | Status | Private | | Employees | ~20 |
Funding History
| Round | Year | Amount | |-------|------|--------| | Series A | 2016 | $17 million | | Series B | 2018 | $22 million | | Series C | 2020 | $30 million | | IPO | 2020 | $45 million | | Reverse Merger | 2024 | -- |
Alzheimer's Disease Programs
PNT001
PNT001 is Pinteon's lead clinical candidate, a monoclonal antibody that selectively binds to pathological conformations of tau protein[@pnt2022].
Mechanism: Monoclonal antibody targeting pathological tau conformations (conformant epitope)
Target: Pathological tau (disease-specific conformers)
Phase: Phase 1 (completed)
Route: Intravenous infusion
Key Features:
Selective for pathological tau forms
Preserves normal tau function
High affinity for AD and CTE tau
Mechanism of Action
PNT001 targets a specific conformational epitope of tau that is exposed only in pathological aggregates. This selective binding allows:
Targeted Clearance: Antibody engages microglia to clear pathological tau while sparing normal tau
Reduced Off-Target: Unlike pan-anti-tau antibodies, PNT001 does not bind functional tau
Disease Modification: By removing toxic tau species, may slow or halt disease progression
Clinical Data
PNT001 completed Phase 1 clinical trials in 2022:
Safety: Well-tolerated at all doses with no serious adverse events
PK: Dose-proportional exposure with half-life supporting monthly dosing
Target Engagement: Demonstrated engagement with pathological tau in CSF biomarkers
Pipeline Programs
PNT002 and PNT003
Pinteon's preclinical pipeline includes next-generation conformant antibodies with:
Enhanced brain penetration
Improved half-life
Dual-targeting capabilities
Tau PET Tracer Partnership
Pinteon has collaborated with imaging partners to develop tau PET tracers that can:
Identify patients with high pathological tau burden
Monitor treatment response
Aid in patient selection for clinical trials
Science and Technology
Conformant™ Platform
Pinteon's proprietary Conformant™ platform enables the discovery of antibodies that selectively target pathological protein conformations. This approach addresses a key limitation of earlier tau immunotherapy efforts[@tau2019].
Advantages over traditional anti-tau antibodies:
Disease-specific targeting
Reduced mechanism-based toxicity
Broader therapeutic window
Potential for earlier intervention
Tau Pathology in Neurodegeneration
Tau protein forms neurofibrillary tangles (NFTs) in Alzheimer's disease, which correlate strongly with cognitive decline. Pathological tau:
Spreads through neural networks in a prion-like manner
Impairs synaptic function
Causes neuronal loss
Predicts clinical progression better than amyloid
Competitive Landscape
| Company | Drug | Mechanism | Phase | |--------|------|-----------|-------| | Biogen | BIIB080 | Tau ASO | Phase 1 | | Eli Lilly | Semorinemab | Anti-tau mAb | Phase 2 (failed) | | Roche/Genentech | Semorinemab | Anti-tau mAb | Phase 2 | | AbbVie | ABBV-8E12 | Anti-tau mAb | Phase 2 | | Axon Neuroscience | AADvac1 | Tau vaccine | Phase 2 | | AC Immune | ACI-35 | Tau vaccine | Phase 2 |